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Abstract
Background: Aberrant expression of A20 has been reported in several human malignancies including
hepatocellular carcinoma (HCC). However, its clinical relevance and potential role in HCC remain unknown.
Methods: Quantitative PCR, Western blots and immunohistochemistry analyses were used to quantify A20
expression in HCC samples and cell lines. The correlation of A20 expression with clinicopathologic features was
analyzed in a cohort containing 143 patients with primary HCC. Kaplan-Meier curves were used to evaluate the
association between A20 expression and patient survival. Functional studies were performed to determine the
effects of A20 on proliferation and metastasis of HCC cells in vitro and in vivo.
Results: Expression of A20 was increased in HCC tissues and cell lines. Increased expression of A20 was negatively
correlated with the tumor size, TNM stage, tumor thrombus formation, capsular invasion and serum AFP levels.
Patients with higher A20 expression had a prolonged disease-free survival and overall survival than those with
lower A20 expression. Forced expression of A20 significantly inhibited the proliferative and invasive properties of
HCC cells both in vitro and in vivo, whereas knockdown of A20 expression showed the opposite effects. Further
studies revealed that expression of A20 was inversely correlated with Twist1 levels and NF-κB activity in HCC tissues
and cell lines. A20-induced suppression of proliferation and migration of HCC cells were mainly mediated through
inhibition of Twist1 expression that was regulated at least partly by A20-induced attenuation of NF-κB activity.
Conclusions: Our results demonstrate that A20 plays a negative role in the development and progression of HCC
probably through inhibiting Twist1 expression. A20 may serve as a novel prognostic biomarker and potential
therapeutic target for HCC patients.
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Introduction
Liver cancer is one of the leading causes of cancer-
related death worldwide and is particularly prevalent in
China. According to data from the International Agency
for Research on Cancer, there were an estimated 782,500
new cases of liver cancer and 745,500 deaths during 2012,
with China alone accounting for about 50 % of the total
number of cases and deaths [1]. Among primary liver
cancers, hepatocellular carcinoma (HCC) represents the
major histological subtype, accounting for 70–85 % of the
total liver cancer burden worldwide [2]. Despite the ad-
vances in diagnosis and treatment, the prognosis of HCC
patients remains dismal due to the high frequency of
tumor recurrence or distant metastasis after surgical re-
section [3]. Therefore, a better understanding of the mo-
lecular mechanisms involved in the pathogenesis and
progression of HCC is particularly important for the de-
velopment of novel therapeutic strategies for the treat-
ment of patients with HCC.
A20, also known as Tumor necrosis factor α-induced
protein 3 (TNFAIP3), was initially identified as a primary
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gene product following tumor necrosis factor α (TNFα)
treatment in human umbilical vein endothelial cells [4].
Previous studies of the A20 gene have focused mainly on
the immunoregulatory aspects. It has been shown that
A20 is a central regulator of cellular immune and inflam-
mation and acts as an ubiquitin-editing enzyme to potently
downregulate NF-κB signaling, thereby functioning as an
important anti-inflammatory factor [5]. Recently, aberrant
expression of A20 has been reported in several human ma-
lignancies and growing evidence supports the notion that
A20 also plays a functional role in cancer development. It
has been identified that A20 is a crucial tumor suppressor
in various lymphomas, such as diffuse large B-cell lymph-
oma, classical Hodgkin's lymphoma, mucosa-associated
tissue lymphoma and the T-cell malignancy-Sezary syn-
drome SS [6–10]. In addition, reduced expression of A20
was also observed in pancreatic cancer tissues [11]. In
contrast to lymphoma and pancreatic cancer, A20 is highly
expressed and responsible for proliferation of glioblast-
omas and bladder cancer [12–15]. These discrepant re-
ports on the role of A20 in different malignances indicate
that its biological function is tissue-dependent and varies
with the type of malignancy [16]. In liver, A20 was mainly
known as a promoter of proliferation based on hepatec-
tomy and liver regeneration experiments in A20 knock-out
mice [17]. Interestingly, Dong et al. recently reported that
A20 was highly expressed in human HCC tissues [18].
Given the potential significance of A20 in cancer pathobi-
ology, its clinical relevance and potential role in human
HCC deserves to be investigated.
Therefore, in the present study, we examined both the
mRNA and protein expression levels of A20 in HCC
tissue samples and cell lines and further analyzed the clin-
ical significance of A20 expression in a cohort of HCC
patients. Moreover, we explored the potential role of A20
in HCC cell proliferation and migration both in vitro and
in vivo. Our findings may shed a new light on the patho-
genesis of HCC and provide a novel therapeutic target for
the treatment of patients with HCC.
Materials and methods
Patients and follow-up
Formalin-fixed paraffin-embedded tissue specimens from
143 primary HCC patients who received curative surgery in
the Eastern Hepatobiliary Surgery Hospital (Shanghai,
China) from September 2008 to June 2010 were retrieved
for immunohistochemistry. Detailed clinicopathologic char-
acteristics of the patients are listed in Table 1. The follow-
up period was defined as the interval from the date of
surgery to the date of death or last follow-up. The latest
follow-up was updated in September 2013. Overall survival
(OS) was defined as the interval from the date of surgery to
the date of death. Patients alive at the end of follow-up
were censored. Disease-free survival (DFS) was defined as
the interval from the date of surgery to the date of disease
recurrence; if recurrence was not diagnosed, patients were
censored on the date of death or last follow-up. Patients
were excluded from the study cohorts with the following
exclusion criteria: previously received any anticancer ther-
apy; impaired heart, lung, liver or kidney function; previous
malignant disease. Tumor stage was classified according to
the 7th Edition tumor-node-metastasis (TNM) classifica-
tion of the American Joint Committee on Cancer Staging.
Fresh-frozen HCC samples obtained from 84 primary HCC
patients who received curative surgery in the Eastern Hepa-
tobiliary Surgery Hospital from October 2012 to July
Table 1 Relationship between Intratumor A20 expression and
clinicopathologic features of HCC patients in the study cohort
A20 expression (n = 143)





≤ 50 52 33
> 50 29 29
Tumor size (cm) 0.007
≤ 5 14 23




















≤ 20U/L 13 21
> 20U/L 68 41
a Pearson chi-square test was used for comparison between subgroups. Bold
type indicates statistical significance
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2013 were used for quantitative polymerase chain reac-
tion (qPCR) and Western blot analysis. Written in-
formed consent was obtained from each patient and
this study was approved by the Ethics Boards of the
Eastern Hepatobiliary Surgery Hospital.
Plasmids and biological reagents
pEF1-A20-wt was a gift from Dr Daniel Krappmann
(Helmholtz Zentrum Munchen Gmbh, German). The
pCSII-H1-PGK- puro-WPRE-shRNA-A20 and control
scramble vector were kindly provided by Prof. Masao
Seto. pBabe-puro-flag-twist1 was kindly provided by
Prof. Alain Puisieux. Lentivirus vector pCDH-CMV-EF1-
GFP-puro purchased from System Biosciences was con-
structed for A20 stable expression. The IκBα plasmid
and the NFκB promoter-luciferase plasmid were pur-
chased from the Addgene.
Cell lines and culture
HCCLM3 cells were transferred from the cell bank of
Zhongshan Hospital, Fudan University Medical College in
2012. HCCLM3 was established in 2003 in Zhongshan
Hospital [19] and stored in liquid nitrogen tank. Normal
liver cell lines QSG-7701 and liver cancer cell lines
SMMC-7721, MHCC-97 L and MHCC-97H were pur-
chased from the Cell Research Institute of Chinese Acad-
emy of Sciences (Shanghai, China). Cells were maintained
at 37 °C in a humidified incubator containing 5 % CO2 in
Dulbecco’s modified Eagle’s medium supplemented with
10 % heat-inactivated fetal bovine serum and passed every
2–3 d to maintain logarithmic growth. Stable knockdown
or overexpression HCCLM3 cells (LM3-shA20 and LM3-
A20, respectively) and their empty vector counterparts
(LM3-shcon and LM3-con, respectively) were generated
using a lentivirus system followed by selected in medium
containing 3 μg/ml puromycin for 2–3 weeks.
Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) containing the specimens
from the Eastern Hepatobiliary Surgery Hospital were
constructed (in collaboration with Shanghai Biochip
Company, Shanghai, China). Immunohistochemistry of
tissue microarray slides was performed as described pre-
viously [20]. Briefly, slides were deparaffinized and rehy-
drated. The endogenous peroxidase activity was blocked
with 3 % H2O2 for 10 min. Antigens were retrieved with
citrate buffer (10 mM, pH 6.0) for 15 min at 100 °C in a
microwave oven. After blocking, the slides were incubated
with a primary anti-A20 antibody (Santa Cruz, 1:50) or a
primary anti-PCNA antibody (CST, 1:4000) at 4 °C over-
night in a moist chamber followed by incubated with an
anti-rabbit or anti-mouse peroxidase-conjugated second-
ary antibody (Santa Cruz) at room temperature for
30 min. Finally, the visualization signal was developed
with 3,3′-diaminobenzidine (Dako) and the slides were
counterstained with hematoxylin. Expression of A20 in
the tissue chip was evaluated in a blinded manner without
prior knowledge of the clinical data using the German
immunoreactive score (IRS) [21]. The median value of the
IRS was chosen as the cut-off for high and low A20
expression levels based on a measure of heterogeneity
according to the log-rank test with respect to the overall
survival as described previously [22, 23].
Real-Time PCR
Real-time qPCR analysis was performed as described
previously [20]. Briefly, Total RNA was prepared using
Trizol (Invitrogen) from liver tumor and non-tumor
tissues, and reversely transcribed into cDNA using M-
MLV Reverse Transcriptase (Promega). Gene primers
were ordered from Sangon Biotech (Shanghai) and SYBR
Green PCR Master Mix was purchased from Takara
Biotechonology Corporation. qPCR was performed on
ABI Prism 7300 Sequence Detection System (Applied
Biosystems) using the 2-ΔΔCT method. Gene expression
results were normalized by internal control β-actin.
Primers used in this study were listed in Additional file
1: Table S1. Each sample was tested in triplicate.
Western blots
Western blot assay was performed as described previ-
ously [20]. Briefly, tumor specimens were prepared in
lysis buffer [Tris-HCl (20 mM), pH 7.4, NaCl (150 mM),
glycerol (10 %), Nonidet P-40 (0.2 %), EDTA (1 mM),
EGTA (1 mM), PMSF (1 mM), NaF (10 mM), aprotinin
(5 mg/ml), leupeptin (20 mM), and sodium orthovana-
date (1 mM)] and centrifuged at 12,000 g for 30 min. Pro-
tein concentrations were measured using the BCA assay.
All samples were prepared to the same concentration
with 4XSDS sample buffer. The proteins were separated
by SDS-PAGE and transferred to nitrocellulose mem-
branes. The primary antibodies specific for A20, Twist1
and β-actin were purchased from Santa Cruz Biotech-
nology. Antibodies for Phospho-NF-κB p65 (Ser536)
(p-p65) and IκBα were from Cell Signaling Technology.
The immunocomplexes were incubated with goat anti-
rabbit or anti-mouse fluorescein-conjugated secondary
antibodies, and then detected using an Odyssey fluores-
cence scanner (Li-Cor, Gene Company).
Transient transfection
For plasmid transfection experiments, cells were transi-
ently transfected using PEI (Polyplus; AFAQ) as described
previously [24]. For RNA interference experiments, siRNA
targeting Twist1 (si Twist1) or corresponding scrambled
siRNA (si con) (Invitrogen) were transfected into cells
using the INTERFERIN transfection reagent (Polyplus) ac-
cording to the manufacturer’s protocol. Gene silencing
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effect was measured by Western blot assay at 60 h post
transfection. The siRNA specific for Twist1 was designed
with the sequence 5′-GAUGGCAAGCUGCAGCUAU-3′
as previously described [25].
NF-κB Luciferase reporter assays
For the luciferase assay, cells were cotransfected with
NF-κB promoter-luc and pRL-TK plasmids (Promega).
After 24 h of transfection, cells were serum starved over-
night followed by treated with or without TNFα (10 ng/
mL) for additional 12 h, and the activities of firefly and
Renilla luciferases were measured using a dual-luciferase
reporter assay system (BioTek Synergy 2). Relative firefly
luciferase activity was normalized by Renilla luciferase
activity. Each point was set in duplication and the exper-
iments were repeated three times.
Cell proliferation assay
Cell proliferation was assessed by cell counts and Bro-
modeoxyuridine (BrdU) incorporation using a commer-
cial kit (Millipore) according to the manufacturer’s
instructions. Briefly, cells were serum free for 24 h. Then
cells were trypsinized and equal number (5 × 103) of cells
from each group was plated into a 96-well plate and
grown in complete culture medium with 10 μM BrdU
for the indicated times. BrdU incorporation was detected
by addition of peroxidase substrate. Spectrophotometric
detection was performed at a wavelength of 450 nm
using a microplate reader (BioTek Synergy 2). Each assay
was done in triplicate and the experiments were re-
peated three times.
Wound-healing, cell migration and invasion assay
Wound healing, Cell migration and invasion assays were
performed as described previously [20]. Briefly, for
wound-healing assays, monolayers of cells plated in 12-
well plate were wounded by scraping with a 200 μL plastic
pipette tip and then rinsed several times with medium to
remove floating cells. The wound healing process was
monitored at the indicated time with an inverted light
microscope (Olympus IX70). For cell migration and inva-
sion assays, Transwell filter chambers (Costar, Corning,
NY) and BioCoat Matrigel invasion chambers (BD Biosci-
ences) were used following the manufacturer’s instruc-
tions. Six random microscopic fields were counted per
field in each group, and these experiments were repeated
at least three independent times.
In vivo metastasis and xenograft tumor assays
In vivo metastasis and xenograft tumor assays was per-
formed as described previously [20]. For pulmonary meta-
static model, five-week-old male nude mice, purchased
from the Animal Center of The Second Military Medical
University, were injected with 1 × 106 cells from LM3-
shcon, LM3-shA20, LM3-con or LM3-A20 through the
tail vein, respectively. Mice were sacrificed at 3 months
post injection. The lungs of each mouse were separated
and fixed for H&E staining and lung metastatic foci were
detected under microscope. For xenograft tumor model,
nude mice were subcutaneously injected with the 2 × 105
indicated cells into the bilateral flanks of each mouse,
respectively. Tumor development was observed weekly
or biweekly with a caliper, and the tumor volume was
calculated using the following formula: larger diam-
eter × (smaller diameter) 2 / 2. All animals were housed
in cages under standard conditions, following the re-
quirements of the Second Military Medical University
Animal Care Facility and the National Institutes of
Health guidelines.
Statistical analysis
Data were presented as the means ± SEM unless other-
wise indicated. Pearson chi-square test or student’s t-test
was applied to assess the statistical significance among
variables. Kaplan-Meier analysis with Log-rank test was
used to compare the patient survival between subgroups.
All statistical analyses were carried out using SPSS
PASW Statistics 18.0 software (SPSS, Inc., Chicago, IL)
and p value < 0.05 were considered to be statistically
significant.
Results
Expression of A20 is increased in HCC tissues and cell lines
To determine the expression pattern of A20 in HCC, we
first quantified the abundance of A20 mRNA in 60 pairs
of HCC and corresponding adjacent non-tumor tissues
using real-time qPCR methods. As showed in Fig. 1a,
A20 mRNA expression was significantly increased in the
tumor tissues compared with adjacent non-tumor tissues
(p < 0.05). In addition, Western blot analysis from an
independent set of 24 paired HCC and adjacent non-
tumor specimens confirmed that A20 protein levels were
significantly higher in cancerous tissues than in adjacent
non-cancerous counterparts (Fig. 1b). Furthermore, we
determined the levels of A20 mRNA and protein in HCC
cell lines and the normal hepatocyte cell line QSG-7701.
Similarly, A20 was significantly upregulated in all HCC
cell lines when compared to the QSG-7701 cells at both
the mRNA and protein levels (Fig. 1c and d). These results
suggest that A20 expression is upregulated in HCC.
Increased A20 expression predicts favorable
clinicopathologic features and prognosis in HCC patients
To further determine the phenotypic expression of A20
protein in HCC clinical samples, immunohistochemical
analysis was performed using a tissue microarray con-
taining 143 pairs of HCC specimens. Each pair consisted
of cancerous and adjacent non-cancerous tissues derived
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from the same patient. The representative staining of A20
protein (negative, weak, moderate, strong) in HCC tissues
was shown in Fig. 2a, and positive staining of A20 was
observed primarily in the cytoplasm. To evaluate the asso-
ciation between A20 expression levels and clinicopatho-
logic characteristics, the patients were classified into high
and low A20 expression subgroups with the median IRS
value as the cut-off. As shown in Table 1, higher levels of
A20 protein were significantly correlated with smaller
tumor size (p = 0.007), lower TNM stage (p < 0.001), lower
incidence of thrombus formation (p = 0.002), lower inci-
dence of capsular invasion (p = 0.038), and lower levels of
serum AFP (p = 0.013). While, there were no significant
associations between A20 expression and sex (p = 0.847),
patient age (p = 0.185), HBsAg (p = 0.078), Liver cirrhosis
(p = 0.389) or capsular formation (p = 0.062).
Kaplan-Meier analysis of the complete study cohort
indicated that patients in the high-A20 expression group
had a significant prolonged disease-free survival (DFS,
median DFS times were 8.6 and 2.4 months, respectively;
difference = 6.2 months; p = 0.004, Fig. 2b) and favorable
overall survival (OS, median OS times were 22.4 and
8.5 months, respectively; difference = 13.9 months; p =
0.011, Fig. 2c) than those in the low-A20 expression
group. More importantly, stage-based survival analyses
revealed that higher levels of A20 significantly predicted
prolonged DFS (p = 0.022, Fig. 2d) and OS (p = 0.041,
Fig. 2e) in patients who had early stage (stages I-II)
tumors. These data indicate that the expression level of
A20 could serve as a valuable indicator for predicting
the prognosis of HCC.
A20 inhibits the proliferation and tumor growth of HCC
cells in vitro and in vivo
In view of the correlation between A20 expression levels
and the aggressive clinical behaviors of HCC patients, it
is speculated that A20 may play a role in HCC develop-
ment and progression. To examine the effects of A20 on
the proliferation of HCC cells, we established A20 over-
expression or knockdown stable HCCLM3 cells (LM3-
Fig. 1 Expression of A20 is upregulated in HCC tissues and cell lines. a A20 mRNA expression in 60 paired human primary HCC tissues and
matched adjacent non-tumor tissues were determined by real-time qPCR methods. Relative A20 mRNA expression results were normalized by
internal control β-actin. *, p < 0.05. b Protein levels of A20 in an independent set of 24 paired HCC and matched adjacent non-tumor specimens
were determined by Western blot assay. β-actin was used as a loading control. (T, tumor tissues; N, adjacent non-tumor tissues) (c-d) Expression
levels of A20 mRNA (c) and protein (d) in QGS-7701 and HCC-derived cell lines
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A20 and LM3-shA20, respectively) and their empty vector
counterparts (LM3-con and LM3-shcon, respectively)
(Fig. 3a). The cell proliferation assay showed that specific
knockdown of A20 in HCCLM3 cells significantly in-
creased cell proliferation, whereas overexpression of A20
in HCCLM3 cells did the opposite (Fig. 3b).
To further verify the growth-inhibitory effect of A20 in
vivo, the xenograft tumor model assays were performed
by subcutaneously injecting LM3-shA20 or LM3-shcon
cells into the dorsal flank of nude mice. As shown in
Fig. 3C, A20 depletion resulted in a significant increase in
tumor growth (p < 0.05). Consistently, results from the
xenograft experiments by injecting LM3-A20 or LM3-con
cells into the dorsal flank of nude mice demonstrated that
A20 overexpression significantly impaired the tumor
growth in vivo (Fig. 3d). In addition, the xenograft tumors
were subjected to immunohistochemical staining of prolif-
erating cell nuclear antigen (PCNA), which is used as a
proliferation marker. More PCNA-positive nuclei were ob-
served in LM3-shA20 xenograft tumors than LM3-shcon
xenograft counterparts (Fig. 3e). Conversely, the number of
PCNA-positive nuclei was apparently decreased in the
Fig. 2 Upregulated A20 expression predicts favorable clinicopathologic features and prognosis in patients with HCC. a Representative
immunohistochemical expression patterns of A20 in cancerous and adjacent normal mucosa specimens are shown. (Magnification, upper panel,
×100; lower panel, ×400) (b-c) Kaplan-Meier curves for disease-free survival (b) and overall survival (c) of all patients in the study cohort according
to A20 expression status. The p-value was determined using the log-rank test. d-e Kaplan-Meier curves for disease-free survival (d) and overall
survival (e) of patients with early stage (stages I-II) tumors according to A20 expression status. The p-value was determined using the log-rank test
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A20-overexpressing group as compared with the control
group (Fig. 3f). These findings demonstrate that A20 plays
a negative role in HCC proliferation.
A20 suppresses the invasion and metastasis of HCC cells
in vitro and in vivo
To determine the roles of A20 in the motility of HCC
cells, scratch wound healing, transwell migration and
matrigel invasion assays were performed in A20 overex-
pression or knockdown HCCLM3 cells. In wound-healing
assay, knockdown of A20 in HCCLM3 cells dramatically
increased cell motility (Fig. 4a), while overexpression of
A20 significantly inhibited this ability (Fig. 4b). In
addition, the transwell migration assay showed that A20
depletion resulted in increased cell migration, whereas
forced expression of A20 exerted the opposite effects.
Moreover, similar results were also observed in the matri-
gel invasion assays (Fig. 4c and d).
To further confirm the metastasis-suppressing role of
A20 in vivo, LM3-shA20 or LM3-shcon cells were
injected into the lateral tail vein of nude mice. Three
months later, more and larger micrometastatic lesions
were detected microscopically in the lungs of nude mice
inoculated with LM3-shA20 cells compared with those
inoculated with LM3-shcon cells (Fig. 4e). By contrast,
three months after LM3-A20 or LM3-con cells were
Fig. 3 A20 suppresses proliferation and tumor growth of HCC cells in vitro and in vivo. a Stable knockdown or overexpression HCCLM3 cells
(LM3-shA20 and LM3-A20, respectively) and their empty vector counterparts (LM3-shcon and LM3-con, respectively) were subjected to Western
blot assay and probed with specific antibodies to A20 and β-actin. b Cell viability was determined by the Brdu cell proliferation assay at indicated
times. Plots are mean ± SEM of data from three independent experiments. *, p < 0.05. c Xenograft tumor model assays. 2x105 of LM3-shcon or
LM3-shA20 cells were subcutaneously injected into the bilateral flanks of nude mice. Representative images of the subcutaneous xenografts are
shown (left upper panel). Subcutaneous xenografts from the LM3-shcon and LM3-shA20 groups were excised from nude mice (n = 4) (left down
panel). The growth curves of xenografts tumor volumes (right panel). *, p < 0.05. d 2 × 105 of LM3-con or LM3-A20 cells were subcutaneously
injected into the bilateral flanks of nude mice. Representative images of the subcutaneous xenografts are shown (left upper panel). Subcutaneous
xenografts from the LM3-con and LM3-A20 groups were excised from nude mice (n = 4) (left down panel). The growth curves of xenografts
tumor volumes (right panel). *, p < 0.05. e-f Indicated xenograft tumors were subjected to H&E and immunohistochemical staining of A20 and
PCNA. Representative images are shown. The scale bars represent 50 μm
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injected into tail vein of nude mice, less and smaller
micrometastatic lesions were observed in the lungs of
nude mice inoculated with LM3-A20 cells than those
inoculated with LM3-con cells (Fig. 4f ). Collectively,
these results indicate that A20 is capable of inhibiting
the invasive and metastatic potential of HCC cells both
in vitro and in vivo.
Downregulation of Twist1 is required for A20-mediated
inhibition of HCC proliferation and migration
To explore the underlying mechanism of A20-mediated
inhibition of proliferation and migration of HCC cells,
we assessed whether A20 is involved in the regulation of
the epithelial-mesenchymal transition (EMT), which is
thought to be a key process for cancer metastasis. Interest-
ingly, among the EMT-related genes examined, Twist1
mRNA expression was found to be significantly decreased
in LM3-A20 cells compared with LM3-con cells. Mean-
while, the Twist1 mRNA level was profoundly increased
in LM3-shA20 cells when compared to control counter-
parts (Fig. 5a). In addition, western blot analysis confirmed
that protein expression of Twist1 was significantly down-
regulated in LM3-A20 cells, while upregulated in LM3-
shA20 cells when compared to their respective control
counterparts (Fig. 5b).
To determine whether Twist1 is involved in A20-
mediated regulation of proliferative and migratory capabil-
ities, rescue experiments in HCCLM3 cells were performed.
Importantly, ectopic expression of Twist1 effectively abro-
gated the A20-mediated inhibition of proliferation and
migration in LM3-A20 cells (Fig. 5c, d and e). Conversely,
specific knockdown of Twist1 expression by siRNA clearly
blocked the increased cell proliferation and migration
caused by A20 depletion in LM3-shA20 cells (Fig. 5f, g, h).
Taken together, these findings suggest that A20-induced
suppression of HCC proliferation and migration is mainly
mediated through inhibition of Twist1 expression.
Decreased NF-κB activity is involved in A20-induced
downregulation of Twist1
Previous studies have demonstrated that A20 negatively
controls NF-κB signaling [26] and Twist1 could be
regulated by NF-κB [27–29], we then determined whether
NF-κB signaling contribute to reduced expression of
Twist1 induced by A20. The effect of A20 expression on
the transcriptional activity of NF-κB was determined by
transient transfection assay using NF-κB-Luc reporter
plasmid. As expected, the NF-κB luciferase activity was
significantly decreased in LM3-A20 cells as compared
with LM3-con cells either with or without TNFα treat-
ment (Fig. 6a). Consistently, LM3-shA20 cells showed
markedly increased NF-κB transcriptional activity when
compared to control cells independent of TNFα treatment
(Fig. 6b). Importantly, activation of NF-κB by TNFα treat-
ment effectively rescued the reduced expression of Twist1
induced by A20 (Fig. 6c). Furthermore, enforced expres-
sion of IκBα, which profoundly inhibited the activity of
NF-κB, blocked the upregulation of Twist1 expression in
LM3-shA20 cells (Fig. 6d). These data indicate that
suppression of Twist1 induced by A20 is mainly NF-κB
dependent.
Expression of A20 is inversely correlated with Twist1
levels and NF-κB activities in HCC tissues and cell lines
To further reveal the relationship between A20, activa-
tion of NF-κB and Twist1 in clinical HCC tissues, we
performed Western blot analysis on protein levels of
A20, p-p65 and Twist1 in human HCC specimens and
cell lines (Fig. 7a and c). Levels of these proteins were nor-
malized to each own level of β-actin. The relative density
of each sample was used for the Pearson correlation ana-
lysis. The results showed that there were significantly
inverse correlation between A20 and Twist 1, or A20 and
p-p65 expression in both HCC tissues and cell lines
(Fig. 7b and d). Collectively, these findings support that
A20-induced effects on the proliferation and migration of
HCC cells are mainly mediated through inverse regulation
of Twist1 expression and the activation of NF-κB.
Discussion
NF-kB has long been implicated in the development of
inflammation and cancer [30]. Persistent activation of
NF-κBin human tumors correlates with a higher inci-
dence of metastasis, faster disease progression, increased
(See figure on previous page.)
Fig. 4 A20 inhibits the invasive and metastatic potential of HCC cells in vitro and in vivo. a-b Cells were plated in 12-well plate and allowed to grow
to confluence. Medium was removed and wounds were introduced by scraping the confluent cell cultures with a 200 μL pipette tip. After treatment
for 72 h, the wound healing process was monitored under an inverted light microscope. Representative results are shown. Magnification, ×100. Plots
(right panel) are mean ± SEM of data from three independent experiments. *, p < 0.05. c-d Effects of A20 depletion (c) or A20 overexpression (d) on
the migration and invasion of HCCLM3 cells were assessed by transwell migration assay and matrigel invasion assay, respectively. Representative results
are shown in the left panel. Graphs below panels are numbers of migrated cells (mean ± SEM) from three independent experiments. *, p < 0.05. (e-f)
LM3-shcon or LM3-shA20 cells (e) or LM3-con or LM3-A20 cells (f) were injected into the tail vein of nude mice (n = 5). Three months post inoculation,
mice were sacrificed and metastatic tumor colonies in the lung were examined microscopically. Representative images of H&E staining of lung
metastatic foci in each group are shown. The number and the length of metastatic nodules in the lungs of each group is measured and presented as
the mean ± SEM below the panels. *, p < 0.05
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tumor recurrence, poorer survival and therapeutic resist-
ance [31]. Previous studies have revealed that activation of
NF-kB signaling could promote HCC development by
maintaining liver inflammatory responses [32–34]. Hence,
inhibition of chronic liver inflammation by targeting the
NF-kB signaling may have a great influence on the pre-
vention of HCC development and progression. Recently, it
has been clarified that A20 plays a primary role in suppress-
ing pro-inflammatory signaling by attenuating NF-κB
signaling via deubiquitylating RIPK1and TRAF6 [5, 35–37],
which are crucial mediators of NF-κB activation. In
addition, increased expression of A20 has been observed in
HCC tissues [18]. Nevertheless, whether aberrant expres-
sion of A20 correlates with disease progression or plays a
role in HCC has not been investigated.
The present study, to our knowledge, is the first to
report the clinical implication and biological relevance
of A20 in the development and progression of HCC.
Using real-time qPCR and Western blot analysis, we
found that A20 was upregulated in HCC tissues and
HCC-derived cell lines at both the mRNA and protein
levels. Our results are consistent with the previous
(See figure on previous page.)
Fig. 5 Downregulation of Twist1 is required for A20-mediated inhibition of proliferation and migration of HCC cells. a The total mRNA of indicated cells
was extracted and the relative mRNA expression levels of EMT related genes were determined using qPCR methods. Results were normalized by β-actin.
*, p < 0.05. b Protein levels of Twist1 in indicated cells were determined by Western blot assays. c Cells were transfected with pBabe-puro-flag-twist1 or
empty vector for 24 h and then cell lysates were subjected to Western blot assay and probed with the indicated antibodies. d The proliferative properties
of the cells treated as described for panel C were determined by the Brdu cell proliferation assay at indicated times. Plots are mean ± SEM of data from
three independent experiments. *, p < 0.05. e The migratory properties of the cells treated as described for panel C were analyzed by transwell migration
assay. Representative results are shown in the upper panel. Plots in the lower panel are mean ± SEM of data from three independent experiments. *,
p< 0.05. f Cells were transfected with Twist1 siRNA (siTwist1, 20nM) or scrambled siRNA (si con, 20nM) for 60 h and then cell lysates were subjected to
Western blot assay and probed with the indicated antibodies. g The proliferative properties of the cells treated as described for panel F were determined
by the Brdu cell proliferation assay at indicated times. Plots are mean ± SEM of data from three independent experiments. *, p < 0.05. h The migratory
properties of the cells treated as described for panel F were analyzed by transwell migration assay. Representative results are shown in the upper panel.
Plots in the lower panel are mean ± SEM of data from three independent experiments. *, p < 0.05
Fig. 6 Decreased NF-κB activity is involved in A20-induced downregulation of Twist1. a-b Indicated cells were cotransfected with NF-κB
promoter-luc (0.5ug/well) and pRL-TK plasmids (20 ng/well). After 24 h of transfection, cells were serum starved overnight followed by treated
with or without TNFα (10 ng/mL) for additional 12 h, and cell lysates were prepared to perform a reporter gene assay. Plots are mean ± SEM of
data from three independent experiments. *, p < 0.05. c Cells were serum starved overnight followed by treated with TNFα (10 ng/mL) for the
indicated times and then cell lysates were harvested and subjected to Western blot assay and probed with the indicated antibodies. d Cells were
transfected with IκBα or empty vector plasmid for 24 h and then cell lysates were harvested and subjected to Western blot assay and probed
with the indicated antibodies
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finding of Dong BF et al. [18], in that they also reported
that A20 was highly expressed in human HCC tissues.
In addition, analyzing the association of A20 expression
with clinicopathologic characteristics in 143 HCC pa-
tients by tissue microarray revealed a significant negative
correlation between A20 expression and tumor size,
thrombus formation, capsular invasion, TNM stage and
serum AFP, which are all hallmarks for poor prognosis
of HCC [38]. These findings suggest that A20 is highly
expressed in a subset of human HCC which shows less
aggressive tumor characteristics. As expected, Kaplan-
Meier analysis indicated that patients with higher A20
expression levels had significant lower recurrence rates
and longer survival times after curative resection. More
importantly, stage-based survival analyses revealed that
higher levels of A20 expression significantly predicted
prolonged DFS and OS especially for patients who had
early stage tumors. Generally speaking, HCC patients
who had early stage tumors (stages I-II) have a favorable
prognosis than those who had advanced stage tumors
(stages III-IV). However, a subgroup of patients with
early stage disease have an increased risk of early recur-
rence and death. Therefore, identification of this high-risk
subgroup of patients would be of particular importance in
the selection of patients for appropriate treatment. Thus,
our results suggest that A20 protein expression status
could be a attractive candidate marker to stratify patients
with early stage HCCs into distinct risk subgroup and
helps to guide individualized treatment.
The significant negative correlation between the ex-
pression level of A20 and the aggressive clinical behav-
iors and poor prognosis of HCC patients prompted us to
investigate whether or not A20 plays a functional role in
HCC development and progression. Indeed, our in vitro
and in vivo experiments demonstrated that depletion of
A20 enhanced the proliferative and invasive potential of
HCC cells and triggered tumor growth and lung metas-
tasis of HCC in nude mice, whereas enforced expression
of A20 exerted the opposite effects. Thus, the results
obtained from the gain-of-function and loss-of-function
experiments clearly suggested a tumor-suppressor role
of A20 in HCC, which was consistent with previous
findings in lymphomas [7, 8, 39]. Interestingly, overex-
pression of A20 in the liver has been shown to promote
hepatocyte proliferation to enhance liver regeneration
[17]. Ferran C and his group previously found that A20
was significantly upregulated in the liver following
partial hepatectomy and had the ability to protect mice
against lethal radical hepatectomy by promoting hepato-
cyte proliferation through downregulation of the cyclin-
dependent kinase inhibitor p21waf1 [40]. In addition,
they recently further found that A20 induced liver
Fig. 7 Expression of A20 is inversely correlated with Twist1 expression and NF-κB activities in HCC tissues and cell lines. a Protein levels of A20, p-p65,
Twist1 and β-actin were determined by Western blots in 18 HCC samples. Representative results are shown. b The relative protein expression of A20,
p-p65 and Twist1 in Fig. 7a was quantified and normalized to β-actin. Correlations between the relative expression of A20 and p-p65 or Twist1 in
human HCC tissues were analyzed with the Pearson correlation formula. c Protein levels of A20, p-p65, Twist1 and β-actin in HCC cell lines were
determined by Western blots. d The relative protein expression of A20, p-p65 and Twist1 in Fig. 7c was quantified and normalized to β-actin.
Correlations between the relative expression of A20 and p-p65 or Twist1 in HCC cell lines were analyzed with the Pearson correlation formula
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regeneration following hepatectomy possibly by activating
IL-6/STAT3 proliferative signaling through epigenetic
downregulation of the negative regulator of IL-6 signaling
and SOCS3 [41]. Moreover, the pro-tumorigenic function
of A20 has also been revealed in several other solid tumors,
such as inflammatory breast cancer [42], nasopharyngeal
carcinoma, head and neck squamous cell carcinoma [43]
and gliomas [13, 15]. In our study, knockdown of A20
clearly enhances the proliferative and invasive potential
of HCC cells and triggers tumor growth and lung
metastasis of HCC in nude mice, whereas overexpres-
sion of A20 exerted the opposite effects. Thus, the
potential role of A20 as a tumor suppressor or tumor
promoter is tissue type-specific and varies with the type
of malignancy.
Twist1, the basic helix-loop-helix domain-containing
transcription factor, is involved in the process of EMT
and has been demonstrated to play a key role in the
metastatic progression of human cancer [44, 45]. Inter-
estingly, in the present work, we found that Twist1 was
significantly downregulated in HCCLM3 cells exogen-
ously expressing A20 while apparently upregulated in
A20-depleted HCCLM3 cells. This observation encour-
aged us to further determine whether Twist1 is involved
in mediating A20 action. Importantly, subsequent ex-
ogenous expression or knockdown experiments verified
the requirement of downregulation of Twist1 expression
for A20-induced suppression of HCC proliferation and
migration. This finding was also in agreement with the
well recognized pro-invasive and pro-proliferative effects
of Twist1 on cancer progression [45–48]. Of note, al-
though expression of Twist1 was significantly altered in
A20-overexpressing or A20-depleting cells, no substan-
tial changes in E-cadherin or N-cadherin expression or
cellular morphological phenotype were observed in this
setting, indicating that A20 may exert its anti-metastatic
potential through a EMT-independent mechanism. In
fact, recent studies have revealed that Twist1 contributes
to tumor invasion and dissemination by regulating the
expression of TIMP1 or MMPs [49–52]. Therefore, the
detailed molecular events downstream of the repressed
expression of Twist1 induced by A20 warrants to be
further determined.
As Twist1 has been reported to be transcriptionally
induced by NF-κB [27–29], we therefore hypothesized
that NF-κB may be involved in the A20-induced down-
regulation of Twist1 expression. Indeed, by activation or
inhibition of NF-κB signaling, our results confirmed
that A20 suppresses Twist1 expression mainly through
inhibition of NF-κB activation. Taken together, our
current findings support the notion that A20 negatively
regulates HCC cell proliferation and metastasis prob-
ably through inhibition of Twist1 expression via attenu-
ating the NF-κB activity.
In conclusion, we reported here, for the first time, that
upregulated A20 expression was significantly associated
with less aggressive clinical behaviors and favorable post-
operative outcome of HCC patients. In addition, A20
functions as a tumor suppressor in the progression and
metastasis of HCC through a mechanism involving in-
hibition of Twist1 expression via suppressing NF-κB
activation. Our findings encourage further investigation
of its potential therapeutic implications in the treatment
of patients with HCC.
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